# US 2017/0274067 A1 · Development of methods for production of a whole virus vaccine candidate stock and novel adaptive mutations in hepatitis c virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0274067 A1
- Document ID: US20170274067A1
- Status: Published application
- Kind: A1
- Application number: 15/126,394
- Filed: 2015-04-16
- Published: 2017-09-28
- Earliest claimed: 2014-04-16
- Assignees: Hvidovre Hospital
- Applicants: Hvidovre Hospital
- Inventors: Christian Kjærulff Mathiesen; Tanja Bertelsen Jensen; Jens Bukh; Judith Margarete Gottwein
- Web page: https://patentgrep.com/patent/US20170274067A1

## CPC

- A61K 39/29: Hepatitis virus
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2770/24221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24251: Methods of production or purification of viral material
- C12N 2770/24261: Methods of inactivation or attenuation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to methods for obtaining a whole virus vaccine candidate stock. The present invention also relates to an inactivated whole virus vaccine candidate stock that can be used for vaccination purposes as well as development of novel high titer virus, which is the preferred virus for this technique.

## Claims

### Claim 1

A method of obtaining a whole virus vaccine candidate stock, the method comprising:
a) providing a cell culture supernatant comprising virus particles,
b) purifying and/or increasing the concentration of the virus particles in cell culture supernatant,
c) optionally, repeating step b),
d) optionally, collecting 1 or more specific fractions obtained from steps b) or c), and
e) obtaining the whole virus vaccine candidate stock.

### Claim at position 2

2-38. (canceled)

### Claim 39 (depends on 1)

The method according to claim 1, wherein the cell culture is grown in a serum free medium.

### Claim 40 (depends on 1)

The method according to claim 1, wherein the medium is an adenovirus expression medium, optionally supplemented with penicillin 100 U/mL and streptomycin 100 μg/mL.

### Claim 41 (depends on 1)

The method according to claim 1, wherein the cell culture is grown on a surface, in a suspension, on beads, in cell factories or bioreactors.

### Claim 42 (depends on 1)

The method according to claim 1, wherein the cells in the cell culture are Huh7.5 cells.

### Claim 43 (depends on 1)

The method according to claim 1, wherein the virus is non-enveloped or enveloped.

### Claim 44 (depends on 1)

The method according to claim 1, wherein the virus belongs to the Flaviviridae family.

### Claim 45 (depends on 1)

The method according to claim 1, wherein the virus is selected from the group consisting of a flavivirus, a hepacivirus, a pegivirus, and a pestivirus.

### Claim 46 (depends on 1)

The method according to claim 1, wherein the virus is selected from the group consisting of yellow fever virus, west nile virus, dengue fever virus, GB virus B, GB virus A, GB virus C, GB virus D, bovine viral diarrhea virus, classical swine fever, hog cholera, HAV, HBV, HCV, HCVcc, sf-HCVcc and genotypes 1-7 of HCV.

### Claim 47 (depends on 1)

The method according to claim 1, wherein the purifying and/or increasing the concentration in step b) and c) is/are performed using centrifugation, ultracentrifugation, density gradient ultracentrifugation, iodixanol cushion centrifugation, sucrose cushion centrifugation, nycodenz cushion centrifugation, cesium chloride cushion, iodixanol gradient centrifugation, sucrose gradient centrifugation, nycodenz gradiend centrifugation, cesium chloride gradient centrifugation, ultracentrifugation pelleting, filtration, clarification, microfiltration, nanofiltration, direct filtration, cross-flow filtration, ultrafiltration, precipitation, polyethylene glycol precipitation, polymer precipitation, polyelectrolyte precipitation, chromatography, column chromatography, porous particle chromatography, membrane chromatography, monolith chromatography, size exclusion chromatography, ion exchange chromatography, or dialysis.

### Claim 48 (depends on 47)

The method according to claim 47, wherein there are 1, 2, 3, 4, 5, 6, or 7 iodixanol or sucrose cushion centrifugations performed.

### Claim 49 (depends on 47)

The method according to claim 47, wherein the filtration is conventional direct filtration, depth or dead end filtration, cut-off filtration. microfiltration, nanofiltration, ultrafiltration, small-scale cross-filtration, or cross-flow filtration.

### Claim 50 (depends on 49)

The method according to claim 49, wherein the cross-flow filtration utilizes hollow-fiber filters selected from the group consisting of MicroKros® Filter Modules, MidiKros® Filter Modules, MidiKros® TC Filter Modules, MiniKros® Sampler Filter Modules, MiniKros® Filter Modules, KrosFlo® Filter Modules, KrosFlo® Max Filter Modules and Vivaflow with molecular weight cut-offs of 500 kDa, 300 kDA, 200 kDa, 100 kDa, 70 kDa, 50 kDa, 30 kDa, 10 kDa, 5 kDa, 3 kDa, or 1 kDa, and optionally with different surface areas.

### Claim 51 (depends on 47)

The method according to claim 47, wherein the precipitation is PEG precipitation.

### Claim 52 (depends on 47)

The method according to claim 47, wherein the ultracentrifugation is selected from the group consisting of iodixanol cushion centrifugation, iodixanol gradient ultracentrifugation, sucrose gradient ultracentrifugation, and ultracentrifugation pelleting.

### Claim 53 (depends on 47)

The method according to claim 47, wherein the chromatography is affinity or sephadex chromatography.

### Claim 54 (depends on 1)

The method according to claim 1, comprising:
a) providing a cell culture supernatant comprising virus particles,
b) purifying and/or increasing the concentration of the cell culture supernatant using cross-flow filtration,
c) purifying and/or increasing the concentration of the product of step b) using 2-6 cushion iodixanol ultracentrifugations,
d) collecting 2-8 fractions from the cushion iodixanol ultracentrifugations,
e) selecting the fractions from the above step d) that contain the most virus particles,
f) purifying and/or increasing the concentration of the product of the above step e) using ultracentrifugation pelleting,
g) purifying and/or increasing the concentration of the product of the above step f) using iodixanol gradient ultracentrifugation,
h) collecting 10-35 fractions from the product of the above step g) and isolating the 2-7 fractions that contain the most virus particles,
i) purifying and/or increasing the concentration of the product of above step h) using sephadex chromatography, and
j) obtaining the whole virus vaccine candidate stock.

### Claim 55 (depends on 1)

The method according to claim 1, comprising:
a) providing a cell culture supernatant comprising virus particles,
b) purifying and/or increasing the concentration of the product of the above step a) using cross-flow filtration,
c) purifying and/or increasing the concentration of the product of the above step b) using 2-6-cushion ultracentrifugations,
d) collecting 2-8 fractions from the cushion ultracentrifugations,
e) selecting the fractions from the above step d) that contain the most virus particles,
f) purifying and/or concentrating the product of the above step e) using small-scale cross-flow filtration,
g) purifying and/or concentrating the product of the above step f) using iodixanol gradient ultracentrifugation,
h) collecting 10-35 fractions from the product of the above step g) and isolating the 2-7 fractions that contain the most virus particles,
i) purifying and/or concentrating the product of the above step h) using sephadex chromatography, and
j) obtaining the whole virus vaccine candidate stock.

### Claim 56

An isolated nucleic acid molecule which encodes a human hepatitis C virus, comprising at least one amino acid mutation selected from the group consisting of R104Q, R114W, I178V, V187A, V235L, T385P, H777Y, L782V, I850L, V866A, Y900C, A1021G, K1118R, A1406G, V1635I, V1692A, A1862V, A1900G, P1908L, T1936A, N2034D, T2055I, D2225G, E2238G, S2248P, V2252A, L2266P, M2275T, I2340T, S2357L, C2419S, A2500S, N2537T, C2723S, V2841A, and L2993H with reference to the H77 reference sequence set forth at GenBank accession number AF009606.

### Claim 57 (depends on 56)

The isolated nucleic acid molecule according to claim 56, wherein the hepatitis C virus is derived from genotype 5a Core-NS2 JFH1-based recombinant SA13/JFH1.

### Claim 58 (depends on 56)

A method for producing a cell, which replicates human hepatitis C virus and produces a virus particle comprising:
introducing a nucleic acid molecule into a cell, wherein said nucleic acid molecule is the nucleic acid of claim 56.
